

Revised Draft Agenda
Biocides Working Group Meeting III-2021
7 – 17 September 2021

WG-III-2021 meetings are held as virtual meetings via WebEx

The time is indicated in Helsinki time.

Tuesday 7 Sep	10:00-17:00	APCP WG
Wednesday 8 Sep	10:00-17:00	APCP WG
Thursday 9 Sep	10:00-17:00	APCP WG
Friday 10 Sep	10:00-17:00	APCP WG
Tuesday 14 Sep	10:00-18:00	TOX WG
Wednesday 15 Sep	10:00-18:00	TOX WG
Thursday 16 Sep	10:30-18:00	TOX WG
Wednesday 8 Sep	10:30-18:00	EFF WG
Friday 10 Sep	10:30-15:00	EFF WG
Tuesday 14 Sep	10:30-18:00	EFF WG
Tuesday 7 Sep	10:30-18:00	ENV WG
Thursday 9 Sep	09:30-18:00	ENV WG
Thursday 16 Sep	10:00-18:00	ENV WG
Friday 17 Sep	10:00-14:00	ENV WG (TBC)

Analytical methods and physico-chemical properties Working Group		
Chair: Bernhard Krebs		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement on the minutes of WG II 2021		<i>For agreement</i>
Item 6 – Outcome of e-consultations and follow-ups (closed session)		eCA
6.1	Possible co-formulants in sodium chloride as precursor for the active substance 'active chlorine generated from sodium chloride by electrolysis' Meeting document: <i>WG III 2021_APCP_6-1</i> <i>For discussion</i>	NL
6.2	Substance identification for active chlorine released from sodium hypochlorite in case of a change of the pH value Meeting document: <i>WG III 2021_APCP_6-2</i> <i>For discussion</i>	NO
6.3	Follow-up of WG II - UA for a product family containing propan-1-ol and propan-2-ol PT 01 (BC-MU051242-25) Meeting document: <i>WG III 2021_APCP_6-3</i> <i>For agreement</i>	CH
6.4	Follow-up of WG II - UA for a product family containing propan-1-ol and propan-2-ol PT 01, 02, 04 (BC-AQ050985-22) Meeting document: <i>WG III 2021_APCP_6-4</i> <i>For agreement</i>	CH
Item 7 – Technical and guidance related issues (closed session)		
7.1	Physical hazards Meeting document: <i>WG III 2021_APCP_7-1</i> <i>For discussion</i>	ECHA

7.2	Revision working group recommendations of in situ generated active substances – APCP part Meeting document: <i>WG III 2021_APCP_7-2</i> <i>For discussion</i>	ECHA
Item 8 - Discussion on Active Substances		eCA
8.1	Ozone generated from oxygen PT 02, 04, 05, 11 Meeting document: <i>WG III 2021_APCP_8-1</i> <i>For agreement</i>	DE
8.2	Alkyl(C12-16)dimethylbenzylammonium chloride (C₁₂₋₁₆-ADBAC/BKC) PT 01, 02 Meeting document: <i>WG III 2021_APCP_8-2</i> <i>For agreement</i>	IT
8.3	Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with supercritical carbondioxide PT 18, 19 Meeting document: <i>WG III 2021_APCP_8-3</i> <i>For agreement</i>	ES
8.4	Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with hydrocarbon solvents PT 18, 19 Meeting document: <i>WG III 2021_APCP_8-4</i> <i>For agreement</i>	ES
8.5	Didecyldimethylammonium chloride(DDAC) PT 01, 02 Meeting document: <i>WG III 2021_APCP_8-5</i> <i>For agreement</i>	IT
Item 9 - Discussions on Union Authorisations		eCA
9.1	UA for a product family containing hydrogen peroxide PT 02 (BC-PP063133-29) Meeting document: <i>WG III 2021_APCP_9-1</i> <i>For agreement</i>	SI
9.2	UA for a product family containing L-(+)-lactic acid PT 01, 02, 03, 04 (BC-RC051007-54) Meeting document: <i>WG III 2021_APCP_9-2</i> <i>For agreement</i>	BE
Item 10 – AoB		

Human Health Working Group		
Chair: Antero Airaksinen		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-II-2021		
<ul style="list-style-type: none"> • <i>WG-II-2021_TOX_6-1</i> • <i>WG-II-2021_TOX_6-2</i> • <i>WG-II-2021_TOX_6-3</i> • <i>WG-II-2021_TOX_6-4</i> • <i>WG-II-2021_TOX_7-1</i> • <i>WG-II-2021_TOX_7-2</i> • <i>WG-II-2021_TOX_7-3</i> • <i>WG-II-2021_TOX_7-4</i> • <i>WG-II-2021_TOX_7-5</i> • <i>WG-II-2021_TOX_7-6</i> • <i>WG-II-2021_TOX_7-7</i> • <i>WG-II-2021_TOX_7-8</i> • <i>WG-II-2021_TOX_7-9</i> • <i>WG-II-2021_TOX_Minutes</i> 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	Ozone generated from oxygen PT 2, 4, 5, 11 Meeting document: <i>WGIII2021_TOX_6-1</i> <div style="text-align: right;"><i>For agreement</i></div>	DE
6.2	Alkyl(C12-16)dimethylbenzylammonium chloride (C₁₂₋₁₆-ADBAC/BKC) PT 1, 2 Meeting document: <i>WGIII2021_TOX_6-2</i> <div style="text-align: right;"><i>For agreement</i></div>	IT
6.3	Didecyldimethylammonium chloride (DDAC) PT 1, 2 Meeting document: <i>WGIII2021_TOX_6-3</i> <div style="text-align: right;"><i>For agreement</i></div>	IT

6.4	Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with supercritical carbondioxide PT 18, 19 Meeting document: <i>WGIII2021_TOX_6-4</i> <i>For agreement</i>	ES
6.5	Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with hydrocarbon solvents PT 18, 19 Meeting document: <i>WGIII2021_TOX_6-5</i> <i>For agreement</i>	ES
6.6	DBNPA: Art 75(1)g request PT 4 Meeting document: <i>WGIII2021_TOX_6-6</i> <i>For agreement</i>	DK
6.7	Cyanamide: Art 75(1)g request PT 3 and 18 Meeting document: <i>WGIII2021_TOX_6-7</i> <i>For agreement</i>	DE
6.8	Peanut Butter: Art 75(1)g request Meeting document: <i>WGIII2021_TOX_6-8</i> <i>For discussion</i>	SECR
6.9	Early WG: Sodium persulphate - ED assessment PT 04 Meeting document: <i>WGIII2021_TOX_6-9</i> <i>For agreement</i>	PT
6.10	Early WG: Sodium cacodylate - ED assessment PT 18 Meeting document: <i>WGIII2021_TOX_6-10</i> <i>For agreement</i>	PT
6.11	Early WG: Etofenprox - ED assessment concerning T-modality PT 8 Meeting document: <i>WGIII2021_TOX_6-11</i> <i>For agreement</i>	AT
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for product family containing hydrogen peroxide PT 02 (BC-PP063133-29) Meeting document: <i>WGIII2021_TOX_7-1</i> <i>For agreement</i>	SI

7.2	UA for product family containing L-(+)-lactic acid PT 01, 02, 03, 04 (BC-RC051007-54) Meeting document: <i>WGIII2021_TOX_7-2</i> <i>For agreement</i>	BE
Item 8 - Technical and guidance related issues		Presenter
8.1	Update on guidance development Meeting document: <i>WGIII2021_TOX_8-1</i> <i>For discussion</i>	SECR
Item 9 – AOB		Presenter
9.1	Other information & lessons learned Meeting document: <i>WGIII2021_TOX_9-1</i> <i>For discussion</i>	SECR

Environment Working Group Chair: Heike Schimmelpfennig		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes of WG-II-2021 <ul style="list-style-type: none"> • WG-II-2021_ENV_6-1 • WG-II-2021_ENV_6-2 • WG-II-2021_ENV_6-3 • WG-II-2021_ENV_7-1 • WG-II-2021_ENV_7-2 • WG-II-2021_ENV_7-3 • WG-II-2021_ENV_7-4 • WG-II-2021_ENV_7-5 • WG-II-2021_ENV_7-6 • WG-II-2021_ENV_7-7 • WG-II-2021_ENV_7-8 • WG-II-2021_ENV_7-9 • WG-II-2021_ENV_General minutes 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	Ozone generated from oxygen PT 2, 4, 5, 11 Meeting document: <i>WGIII2021_ENV_6-1</i>	<i>For agreement</i>
6.2	Alkyl(C12-16)dimethylbenzylammonium chloride (C₁₂₋₁₆-ADBAC/BKC) PT 1, 2 Meeting document: <i>WGIII2021_ENV_6-2</i>	<i>For agreement</i>

6.3	Didecyldimethylammonium chloride (DDAC) PT 1, 2 Meeting document: <i>WGIII2021_ENV_6-3</i> <i>For agreement</i>	IT
6.4	Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with supercritical carbondioxide PT 18, 19 Meeting document: <i>WGIII2021_ENV_6-4</i> <i>For agreement</i>	ES
6.5	Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with hydrocarbon solvents PT 18, 19 Meeting document: <i>WGIII2021_ENV_6-5</i> <i>For agreement</i>	ES
6.6	DBNPA: Art 75(1)g request PT 4 Meeting document: <i>WGIII2021_ENV_6-6</i> <i>For agreement</i>	DK
6.7	Cyanamide: Art 75(1)g request PT 3, 18 Meeting document: <i>WGIII2021_ENV_6-7</i> <i>For agreement</i>	DE
6.8	Early WG: CHDG, Chlorhexidine - ED assessment PT 01, 02, 03 Meeting document: <i>WGIII2021_ENV_6-8</i> <i>For agreement</i>	PT
6.9	Early WG: sodium cacodylate - ED assessment PT 18 Meeting document: <i>WGIII2021_ENV_6-9</i> <i>For agreement</i>	PT
6.10	Early WG: K-HDO (RNL): Emission scenario for scaffolding boards PT 08 Meeting document: <i>WGIII2021_ENV_6-10</i> <i>For agreement</i>	AT

Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for a product family containing hydrogen peroxide PT 02 (BC-PP063133-29) Meeting document: <i>WGIII2021_ENV_7-1</i> <i>For agreement</i>	SI
7.2	UA for a product family containing L-(+)-lactic acid PT 01, 02, 03, 04 (BC-RC051007-54) Meeting document: <i>WGIII2021_ENV_7-2</i> <i>For agreement</i>	BE
Item 8 – AOB		
8.1	Other information & lessons learned SECR to inform <i>For information</i>	SECR
8.2	Discussion on warning sentences for bees Meeting document: <i>WGIII2021_ENV_8-2</i> <i>For discussion</i>	SECR

Efficacy Working Group		
Chair: Kasia Szymankiewicz		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-II-2021		
<ul style="list-style-type: none"> • WG-II-2021_EFF_6-1 • WG-II-2021_EFF_7-1 • WG-II-2021_EFF_7-2 • WG-II-2021_EFF_7-3 • WG-II-2021_EFF_7-4 • WG-II-2021_EFF_7-5 • WG-II-2021_EFF_7-6 • WG-II-2021_EFF_7-7 • WG-II-2021_EFF_7-8 • WG-II-2021_EFF_7-9 • WG-II-2021_EFF_Minutes 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	Ozone generated from oxygen PT 2, 4, 5, 11 Meeting document: <i>WGIII2021_EFF_6-1</i> <div style="text-align: right;"><i>For agreement</i></div>	DE
6.2	Alkyl(C12-16)dimethylbenzylammonium chloride (C₁₂₋₁₆-ADBAC/BKC) PT 1, 2 Meeting document: <i>WGIII2021_EFF_6-2</i> <div style="text-align: right;"><i>For agreement</i></div>	IT
6.3	Didecyldimethylammonium chloride (DDAC) PT 1, 2 Meeting document: <i>WGIII2021_EFF_6-3</i> <div style="text-align: right;"><i>For agreement</i></div>	IT

6.4	Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with supercritical carbondioxide PT 18, 19 Meeting document: <i>WGIII2021_EFF_6-4</i> <i>For agreement</i>	ES
6.5	Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with hydrocarbon solvents PT 18, 19 Meeting document: <i>WGIII2021_EFF_6-5</i> <i>For agreement</i>	ES
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for a product family containing hydrogen peroxide PT 02 (BC-PP063133-29) Meeting document: <i>WGIII2021_EFF_7-1</i> <i>For agreement</i>	SI
7.2	UA for a product family containing L-(+)-lactic acid PT 01, 02, 03, 04 (BC-RC051007-54) Meeting document: <i>WGIII2021_EFF_7-2</i> <i>For agreement</i>	BE
Item 8 - Technical and guidance related issues		
8.1	Antimicrobial resistance - draft guidance Meeting document: <i>WGIII2021_EFF_8-1</i> <i>For discussion</i>	FR
8.2	TAB proposals <ul style="list-style-type: none"> • PT18: Crack and crevice treatment Meeting document: <i>WGIII2021_EFF_8-2a</i> • Evaluation of attractants in PT 18 bait products Meeting document: <i>WGIII2021_EFF_8-2b</i> <i>For discussion</i>	NL/DE
Item 9 – AOB		
9.1	Art. 75(1)(g) request – opinion on rodent traps (closed session) Meeting document: <i>WGIII2021_EFF_9-1</i> <i>For discussion</i>	ECHA
9.2	PT14: Permanent baiting in sewers – efficacy data (closed session) Meeting document: <i>WGIII2021_EFF_9-2</i> <i>For discussion</i>	SI

9.3	Other information Meeting document: <i>WGIII2021_EFF_9-3</i> <i>For information</i>	ECHA
------------	--	------